

May 30, 2014.

To,
The Listing Department
National Stock Exchange of India Limited
Exchange Plaza, Plot no. C/1, G Block,
Bandra-Kurla Complex
Bandra (E), Mumbai - 400 051.

Respected Sir,

Scrip Code : KILITCH

Sub: OUTCOME OF THE BOARD MEETING HELD ON FRIDAY, MAY 30, 2014.

With reference to the above captioned subject, we wish to intimate your esteemed exchange that as decided in the Meeting of the Board of Directors of the Company held today, i.e. on Friday, May 30, 2014 at its Administrative Office at Mumbai, for which intimation was already given to you, the Board of Directors has:

- Approved and taken on record the Audited Financial Results of the Company for the quarter and year ended March 31, 2014 along with the Auditors Report thereon.
- Renamed the following committees of the Company as under:

Existing Name of Committees	Revised names of the Committees
Shareholders Grievance Committee	Stakeholders Relationship Committee
Remuneration Committee	Nomination and Remuneration Committee

Further, the Board of Directors unanimously agreed to constitute any other committee(s), by whatever names called, if required under any provisions of the Act or the Rules made there under.

The above intimation is given to you for your record.

Thanking You,

Yours faithfully,

For **KILITCH DRUGS (INDIA) LIMITED**


MUKUND MEHTA
MANAGING DIRECTOR



KILITCH DRUGS (INDIA) LIMITED

CIN. L24239MH1992PLC066718

FINANCIAL RESULTS FOR THE QUARTER ENDED 31ST MARCH 2014

Regd. Office:- C-301/2, MIDC, TTC Industrial Area, Pawane Village, Thane-400701


Rs. (In Lacs)


Particulars	As at 31st March,2014 (Rs.) Audited	As at 31st March,2013 (Rs.) Audited
<u>EQUITY AND LIABILITIES</u>		
Shareholders' funds		
Share capital	1,323.18	1,323.18
Reserves and surplus	10,699.65	10,582.00
Non-current liabilities		
Deferred tax liabilities (Net)	15.08	25.43
Current liabilities		
Trade payables	468.03	1,347.76
Other current liabilities	353.26	371.83
Short-term provisions	47.70	36.30
TOTAL	12,906.90	13,686.50
<u>ASSETS</u>		
Non-current assets		
Fixed assets		
Tangible assets	927.33	874.63
Intangible assets	5.93	12.77
Non-current investments	119.70	71.58
Long-term loans and advances	2,268.62	111.83
Current assets		
Current investments	3,916.33	10,827.71
Inventories	259.90	153.92
Trade receivables	863.39	1,239.79
Cash and Bank balances	4,385.26	294.07
Short-term loans and advances	160.44	100.20
TOTAL	12,906.90	13,686.50

For and on behalf of the Board of Directors

Mumbai

Dated: 30th May, 2014


Mukund P. Mehta
(Managing Director)




KILITCH DRUGS (INDIA) LIMITED

CIN. L24239MH1992PLC066718

AUDITED FINANCIAL RESULTS FOR THE QUARTER ENDED 31ST MARCH 2014

Regd. Office:- C-301/2, MIDC, TTC Industrial Area, Pawane Village, Thane-400701

PART I		Rs. In Lacs				
Sr. No.	Particulars	Three Months Ended			Year ended	Year ended
		31/03/2014	31/12/2013	31/03/2013	31/03/2014	31/03/2013
		Audited	Unaudited	Audited	Audited	Audited
1	Income from operations					
	(a) Net Sales/Income from operations(net of Excise)	633.57	131.16	783.26	1421.49	3199.01
	(b) Other operating income	(20.31)	21.62	119.07	68.31	119.07
	Total income from Operations (Net)	613.26	152.78	902.33	1489.80	3318.08
2	Expenses					
	(a) Cost of materials consumed	406.34	98.21	704.34	774.77	2659.83
	(b) Changes in inventories of finished goods, work-in-progress and stock-in-trade	25.76	(173.32)	1.68	(145.96)	26.13
	(c) Employee Benefit Expenses	90.08	71.45	77.30	285.76	303.45
	(d) Depreciation and Amortisation Expenses	44.94	33.11	24.45	143.97	122.90
	(e) Export Product Registration Charges	111.87	24.08	3.51	183.18	108.00
	(f) Other Expenses	363.01	147.44	183.79	770.89	595.06
	Total Expenses	1042.00	201.01	995.07	2012.62	3815.36
3	Profit / (Loss) from operations before other income, finance costs and exceptional items (1-2)	(428.74)	(48.23)	(92.74)	(522.82)	(497.28)
4	Other Income	174.86	144.18	123.45	629.12	921.53
5	Profit / (Loss) from ordinary activities before finance cost and exceptional items (3+4)	(253.88)	95.95	30.71	106.29	424.25
6	Finance Costs	0.00	0.00	(5.26)	0.00	1.22
7	Profit / (Loss) from ordinary activities before exceptional items (5-6)	(253.88)	95.95	35.97	106.29	423.03
8	Exceptional Items	0.00	0.00	0.00	0.00	0.00
9	Profit / (Loss) from ordinary activities before tax (7+8)	(253.88)	95.95	35.97	106.29	423.03
10	Tax Expenses					
	Current Tax	(60.00)	14.70	0.00	0.00	0.00
	Deferred Tax	(8.34)	0.40	(2.71)	(10.35)	(0.71)
	Tax Adjustments of Earlier years	(1.00)			(1.00)	0
11	Net Profit / (Loss) from ordinary activities after tax (9-10)	(184.53)	80.83	38.68	117.65	423.74
12	Extra Ordinary Items (net of tax expenses)	0.00	0.00	95.46	0.00	95.46
13	Net Profit / (Loss) for the period (11+12)	(184.53)	80.83	(56.78)	117.65	328.28
14	Paid-Up equity share capital (Face Value Rs 10 per share)	1323.18	1323.18	1323.18	1323.18	1323.18
15	Reserve excluding Revaluation Reserve (As per the latest Audited Balance Sheet)				10699.65	10582.00
16.i	Earnings per share (before extra ordinary items) (F.V. of Rs.10/-each) (not annualised):					
	(a) Basic	(1.39)	0.61	0.29	0.89	3.20
	(b) Diluted	(1.39)	0.61	0.29	0.89	3.15
16.ii	Earnings per share (after extra ordinary items) (F.V. of Rs.10/-each) (not annualised):					
	(a) Basic	(1.39)	0.61	(0.43)	0.89	2.48
	(b) Diluted	(1.39)	0.61	(0.43)	0.89	2.44



PART II	Particulars	Three Months Ended			Year ended	Year ended
		31/03/2014	31/12/2013	31/03/2013	31/03/2014	31/03/2013
A	PARTICULARS OF SHAREHOLDING					
1	Public shareholding					
	a) Number of shares	4697655	4697655	4706393	4697655	4706393
	b) Percentage of shareholding	35.50	35.50	35.57	35.50	35.57
2	Promoters and Promoter Group Shareholding					
	a) Pledge / Encumbered					
	Number of shares					
	Percentage of shares (as a % of the total shareholding of promoter and promoter group)					
	Percentage of shares (as a % of the total share capital of the company)					
	b) Non- encumbered					
	Number of shares	8534173	8534173	8525435	8534173	8525435
	Percentage of shares (as a % of the total shareholding of promoter and promoter group)	100	100	100	100	100
	Percentage of shares (as a % of the total share capital of the company)	64.50	64.50	64.43	64.50	64.43

B	INVESTOR COMPLAINTS	
	Pending at the beginning of the Quarter	NIL
	Received during the quarter	1
	Disposed off during the quarter	1
	Remaining unresolved at the end of the quarter	NIL

Notes:

- The above results as reviewed by the audit committee have been taken on record by the Board of Directors at their meeting held on 30th May, 2014.
- During the quarter, the Company has operated only in one reportable segment i.e. Pharmaceuticals.
- The figures for the corresponding previous periods have been restated/regrouped, wherever necessary, to make them comparable with the current periods. Figures of last quarter are the balancing figures between audited figures in respect of the full financial year and published year to date figures upto the third quarter of the current financial year.

Place : Mumbai
Date : 30th May, 2014

For and on Behalf of the Board

MUKUND P. MEHTA
(Managing Director)

